Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

TwinStrand Biosciences

TwinStrand Biosciences
2015 FOUNDED
PRIVATE STATUS
21-30 EMPLOYEES
Series A LATEST DEAL TYPE
$16.3M LATEST DEAL AMOUNT
7 INVESTORS
Description

Developer of a next generation DNA sequencing therapy designed to detect ultra-rare variants of DNA molecules that are invisible by other sequencing approaches. The company's technique uses specialized adapters to uniquely tag both strands of individual DNA duplexes in a population, sequence and using proprietary software, read both strands of individual DNA molecules enabling researchers to get a new generation of high-accuracy clinical diagnostics and innovative tools for scientific discovery.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore TwinStrand Biosciences’s full profile, request a free trial.

TwinStrand Biosciences Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC (Series A) 30-Dec-2019 $16.3M 000.00 Completed Generating Revenue
4. Grant 00.00 00.00 Completed Generating Revenue
3. Grant 01-Jan-2018 00.00 00.00 Completed Generating Revenue
2. Grant 01-Jan-2018 $2.3M $6.1M Completed Generating Revenue
1. Seed Round 13-Sep-2017 $6.1M $6.1M 000.00 Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

TwinStrand Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Seed 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
To view this company’s complete Cap Table, request access »

TwinStrand Biosciences Competitors (33)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Stratos Genomics Venture Capital-Backed Seattle, WA 00 000.00 00000000000 000.00
000000 Venture Capital-Backed Providence, RI 00 0000 0000000000 0 0000
0000000 000000000 Venture Capital-Backed Cambridge, United Kingdom 00 0000 00000000000 0000
00000000 0000000 0 Venture Capital-Backed Castel Maggiore, Italy 0000 000000&0 0000
00000000000 Corporate Backed or Acquired Bothell, WA 000000&0
To view this company’s complete list of competitors, request access »

TwinStrand Biosciences Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
Madrona Venture Group Venture Capital Minority 000 0000 000000 0
Ridgeback Capital Other Minority 000 0000 000000 0
Sahsen Ventures Venture Capital Minority 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

TwinStrand Biosciences Executive Team (4)

Name Title Board
Seat
Contact
Info
Jesse Salk Ph.D Co-Founder, Chief Executive Officer, Chief Scientific Officer & Board Member

3 Former Executives

You’re viewing 1 of 4 executives. Get the full list »

TwinStrand Biosciences Board Members (10)

Name Representing Role Since Contact
Info
Chad Waite Jr. The W Fund Chairman of the Board 000 0000
Jesse Salk Ph.D TwinStrand Biosciences Co-Founder, Chief Executive Officer, Chief Scientific Officer & Board Member 000 0000
Steve Dow Self Board Member 000 0000
Terry Myerson TwinStrand Biosciences Board Member 000 0000

6 Former Board Members

You’re viewing 4 of 10 board members. Get the full list »